Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
株式のランク #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
株価
$0.00023723
最終同期: 2024-08-26
時価総額
$1.41K
変化(1日)
111.67%
変化(1年)
0.00%
FR
取引 Pharnext S.A. (ALPHA)

カテゴリー

Pharnext S.A.(ALPHA)の収益
Dec 2023 時点の収益 TTM: $-487.61K
Pharnext S.A. の最新の財務報告によると、現在の収益 (TTM) は $-487.61K です。2022 年には $598.55 の収益があり、これは 2021 年の $96.41K と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Pharnext S.A. の収益履歴(2013 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $-487.61K -4,510.88%
2023 $11.05K 1,746.90%
2022 $598.55 -99.38%
2021 $96.41K 98.76%
2020 $48.51K -82.90%
2019 $283.61K -96.39%
2018 $7.85M 96.92%
2017 $3.99M -14.33%
2016 $4.65M 62.80%
2015 $2.86M -14.35%
2014 $3.34M -7.92%
2013 $3.62M 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B -2,589,130.69%
US
$6.02B -1,234,964.32%
NL
- -
CH
$10.11B -2,073,651.57%
BE
- -
KR